Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Prevention and early detection of prostate cancer.

In English

Författare

  • Jack Cuzick
  • Mangesh A Thorat
  • Gerald Andriole
  • Otis W Brawley
  • Powel H Brown
  • Zoran Culig
  • Rosalind A Eeles
  • Leslie G Ford
  • Freddie C Hamdy
  • Lars Holmberg
  • Dragan Ilic
  • Timothy J Key
  • Carlo La Vecchia
  • Hans Lilja
  • Michael Marberger
  • Frank L Meyskens
  • Lori M Minasian
  • Chris Parker
  • Howard L Parnes
  • Sven Perner
  • Harry Rittenhouse
  • Jack Schalken
  • Hans-Peter Schmid
  • Bernd J Schmitz-Dräger
  • Fritz H Schröder
  • Arnulf Stenzl
  • Bertrand Tombal
  • Timothy J Wilt
  • Alicja Wolk
Visa allt

Summary, in English

Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

Publiceringsår

2014

Språk

Engelska

Sidor

484-492

Publikation/Tidskrift/Serie

The Lancet Oncology

Volym

15

Issue

11

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Cancer and Oncology

Status

Published

Forskningsgrupp

  • Clinical Chemistry, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1474-5488